Compounds > satavaptan
Page last updated: 2024-09-04

satavaptan and Acquired Nephrogenic Diabetes Insipidus

satavaptan has been researched along with Acquired Nephrogenic Diabetes Insipidus in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheung, CC; Ersoy, B; Favre, H; Miller, WL; Ranadive, SA; Rosenthal, SM; Vaisse, C1
Boone, M; Deen, PM; Kortenoeven, M; Robben, JH1
Bernier, V; Bichet, DG; Bockenhauer, D; Bouvier, M; Breton, B; Carpentier, E; Rochdi, D; van't Hoff, W1
Deen, PM; Knoers, NV; Robben, JH; Sze, M1
Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A1

Other Studies

5 other study(ies) available for satavaptan and Acquired Nephrogenic Diabetes Insipidus

ArticleYear
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
    Clinical endocrinology, 2009, Volume: 71, Issue:3

    Topics: Antidiuretic Hormone Receptor Antagonists; Cell Line; Cell Membrane; Diabetes Insipidus, Nephrogenic; Genetic Diseases, X-Linked; Humans; Infant; Male; Morpholines; Mutation; Protein Transport; Receptors, Vasopressin; Spiro Compounds

2009
Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Arginine; Arginine Vasopressin; Atrial Natriuretic Factor; Cell Line; Cells, Cultured; Cyclic GMP; Diabetes Insipidus, Nephrogenic; Humans; Kidney Tubules, Collecting; Male; Models, Animal; Morpholines; Protein Biosynthesis; Receptors, Vasopressin; Signal Transduction; Spiro Compounds

2010
Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus.
    Nephron. Physiology, 2010, Volume: 114, Issue:1

    Topics: Adolescent; Adult; Amino Acid Substitution; Child; Cyclic AMP; Deamino Arginine Vasopressin; Diabetes Insipidus, Nephrogenic; Female; Gene Expression Regulation; Genetic Diseases, X-Linked; HEK293 Cells; Humans; Infant; Male; Middle Aged; Morpholines; Mutation; Natriuresis; Pedigree; Phenotype; Polyuria; Protein Binding; Receptors, Vasopressin; Recombinant Fusion Proteins; Retrospective Studies; Second Messenger Systems; Spiro Compounds; Transfection; Urine; X Chromosome Inactivation; Young Adult

2010
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    American journal of physiology. Renal physiology, 2007, Volume: 292, Issue:1

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Antigens, Surface; Binding, Competitive; Blotting, Western; Cell Line; Cell Membrane; Cyclic AMP; Diabetes Insipidus, Nephrogenic; Dogs; Electrophoresis, Polyacrylamide Gel; Green Fluorescent Proteins; Immunohistochemistry; Indoles; Kidney; Molecular Chaperones; Morpholines; Mutation; Pyrrolidines; Receptors, Vasopressin; Spiro Compounds; Transfection

2007
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    The Journal of clinical investigation, 2000, Volume: 105, Issue:7

    Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds

2000